{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:32:39Z","timestamp":1788942759542,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1053\/j.akdh.2024.05.002","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T20:02:46Z","timestamp":1720814566000},"page":"223-233","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Update on C3 Glomerulopathy"],"prefix":"10.1053","volume":"31","author":[{"given":"Benjamin","family":"Wooden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla M.","family":"Nester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Bomback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.akdh.2024.05.002_bib1","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/ki.2013.377","article-title":"C3 glomerulopathy: consensus report","volume":"84","author":"Pickering","year":"2013","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.002_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41581-018-0107-2","article-title":"C3 glomerulopathy - understanding a rare complement-driven renal disease","volume":"15","author":"Smith","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.04700513","article-title":"C3 glomerulopathy: clinicopathologic features and predictors of outcome","volume":"9","author":"Medjeral-Thomas","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib4","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2017.10.022","article-title":"C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy","volume":"93","author":"Bomback","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.002_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050712","article-title":"Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy","volume":"12","author":"Kovala","year":"2023","journal-title":"Cells"},{"issue":"9","key":"10.1053\/j.akdh.2024.05.002_bib6","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/ckj\/sfac108","article-title":"Development and validation of a nomogram to predict kidney survival at baseline in patients with C3 glomerulopathy","volume":"15","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1053\/j.akdh.2024.05.002_bib7","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","article-title":"Validation of a histologic scoring index for C3 glomerulopathy","volume":"77","author":"Caravaca-Font\u00e1n","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.002_bib8","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.ajkd.2018.09.002","article-title":"Kidney transplantation in C3 glomerulopathy: a case series","volume":"73","author":"Regunathan-Shenk","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/cr.2009.139","article-title":"Complement and its role in innate and adaptive immune responses","volume":"20","author":"Dunkelberger","year":"2010","journal-title":"Cell Res"},{"issue":"9","key":"10.1053\/j.akdh.2024.05.002_bib10","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s00018-016-2418-4","article-title":"Complement factor H in host defense and immune evasion","volume":"74","author":"Parente","year":"2017","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib11","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1681\/ASN.2012060571","article-title":"Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency","volume":"24","author":"Ruseva","year":"2013","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.002_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.kint.2020.09.028","article-title":"Complement activity is regulated in C3 glomerulopathy by IgG-factor H fusion proteins with and without properdin targeting domains","volume":"99","author":"Gilmore","year":"2021","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/ng912","article-title":"Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H","volume":"31","author":"Pickering","year":"2002","journal-title":"Nat Genet"},{"issue":"25","key":"10.1053\/j.akdh.2024.05.002_bib14","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0601094103","article-title":"Prevention of C5 activation ameliorates spontaneous and experimental glomerulonephritis in factor H-deficient mice","volume":"103","author":"Pickering","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1053\/j.akdh.2024.05.002_bib15","doi-asserted-by":"crossref","first-page":"886","DOI":"10.3389\/fimmu.2019.00886","article-title":"Nephritic factors: an overview of classification, diagnostic tools and clinical associations","volume":"10","author":"Corvillo","year":"2019","journal-title":"Front Immunol"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/ki.2012.63","article-title":"Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies","volume":"82","author":"Servais","year":"2012","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.002_bib17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/ajmg.c.31986","article-title":"C3 glomerulopathy: understanding an ultra-rare complement-mediated renal disease","volume":"190","author":"Heiderscheit","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"6","key":"10.1053\/j.akdh.2024.05.002_bib18","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1172\/JCI68280","article-title":"C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation","volume":"123","author":"Tortajada","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/imr.13168","article-title":"The susceptibility of the kidney to alternative pathway activation-A hypothesis","volume":"313","author":"Thurman","year":"2023","journal-title":"Immunol Rev"},{"issue":"6 suppl 1","key":"10.1053\/j.akdh.2024.05.002_bib20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3949\/ccjm.90.e-s1.01","article-title":"C3 glomerulopathy","volume":"90","author":"Mehdi","year":"2023","journal-title":"Cleve Clin J Med"},{"issue":"8","key":"10.1053\/j.akdh.2024.05.002_bib21","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2018.05.019","article-title":"C3 glomerulopathy: ten years\u2019 experience at mayo clinic","volume":"93","author":"Ravindran","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2215\/CJN.03480708","article-title":"Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients","volume":"4","author":"Nasr","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3109\/13816810.2015.1101777","article-title":"Retinal disease in the C3 glomerulopathies and the risk of impaired vision","volume":"37","author":"Savige","year":"2016","journal-title":"Ophthalmic Genet"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.002_bib24","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1053\/j.ackd.2019.12.003","article-title":"C3 glomerulopathy: pathogenesis and treatment","volume":"27","author":"Ahmad","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"issue":"7","key":"10.1053\/j.akdh.2024.05.002_bib27","doi-asserted-by":"crossref","first-page":"994","DOI":"10.2215\/CJN.16801221","article-title":"Association of histologic parameters with outcome in C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis","volume":"17","author":"Lomax-Browne","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.002_bib28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.34067\/KID.0000000000000115","article-title":"Clinical profiles and patterns of kidney disease progression in C3 glomerulopathy","volume":"4","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Kidney360"},{"issue":"4S","key":"10.1053\/j.akdh.2024.05.002_bib29","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of glomerular diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.002_bib30","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000479012","article-title":"Immunosuppressive treatment in C3 glomerulopathy: is it really effective?","volume":"46","author":"Caliskan","year":"2017","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.002_bib31","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/ki.2015.227","article-title":"Effectiveness of mycophenolate mofetil in C3 glomerulonephritis","volume":"88","author":"Rabasco","year":"2015","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.002_bib32","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2215\/CJN.09080817","article-title":"Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series","volume":"13","author":"Avasare","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.akdh.2024.05.002_bib33","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2215\/CJN.15241219","article-title":"Mycophenolate mofetil in c3 glomerulopathy and pathogenic drivers of the disease","volume":"15","author":"Caravaca-Font\u00e1n","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.002_bib34","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.002_bib35","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1093\/ndt\/gfab302","article-title":"C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies","volume":"37","author":"Caravaca-Font\u00e1n","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.akdh.2024.05.002_bib36","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.002_bib37","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2215\/CJN.12901211","article-title":"Eculizumab for dense deposit disease and C3 glomerulonephritis","volume":"7","author":"Bomback","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2017.11.019","article-title":"Patterns of clinical response to eculizumab in patients with C3 glomerulopathy","volume":"72","author":"Le Quintrec","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib39","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12882-023-03058-9","article-title":"Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study","volume":"24","author":"Welte","year":"2023","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.05.002_bib40","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.ekir.2022.01.124","article-title":"POS-112 effect of avacopan, a selective C5A receptor inhibitor, on complement 3 glomerulopathy histologic index of disease chronicity","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1053\/j.akdh.2024.05.002_bib41","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","article-title":"Efficacy and safety of iptacopan in patients with C3 glomerulopathy","volume":"8","author":"Wong","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.akdh.2024.05.002_bib42","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.ekir.2022.07.004","article-title":"Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy-study design of the APPEAR-C3G trial","volume":"7","author":"Bomback","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"10","key":"10.1053\/j.akdh.2024.05.002_bib43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1159\/000527167","article-title":"Clinical outcomes of patients with C3G or IC-MPGN treated with the factor D inhibitor danicopan: final results from two phase 2 studies","volume":"53","author":"Nester","year":"2022","journal-title":"Am J Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2024.05.002_bib44","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1053\/j.akdh.2024.05.002_bib45","series-title":"ASN Kidney Week","article-title":"Efficacy of 12-week pegcetacoplan in kidney transplant recipients with recurrent C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)","author":"Bomback","year":"2023"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.ki.5000269","article-title":"Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)","volume":"70","author":"Licht","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.05.002_bib47","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jca.10026","article-title":"Management of membranoproliferative glomerulonephritis type II with plasmapheresis","volume":"17","author":"Kurtz","year":"2002","journal-title":"J Clin Apher"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib48","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.kint.2018.04.004","article-title":"Aliskiren inhibits renin-mediated complement activation","volume":"94","author":"B\u00e9k\u00e1ssy","year":"2018","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.05.002_bib49","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1681\/ASN.2013070715","article-title":"Clinical findings, pathology, and outcomes of C3GN after kidney transplantation","volume":"25","author":"Zand","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2024.05.002_bib50","first-page":"44","article-title":"Treatment of C3 glomerulopathy in adult kidney transplant recipients: a systematic review","volume":"8","author":"Gonzalez Suarez","year":"2020","journal-title":"Med Sci (Basel)"},{"issue":"1","key":"10.1053\/j.akdh.2024.05.002_bib51","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ndt\/gfac148","article-title":"Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation","volume":"38","author":"Caravaca-Font\u00e1n","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924000843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T23:03:58Z","timestamp":1720825438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924000843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2949813924000843"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.05.002","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on C3 Glomerulopathy","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}